Andrx Holders Approve Watson Deal
Generic-drug maker Andrx (ADRX) says its shareholders have endorsed a $25-a-share buyout from rival Watson Pharmaceuticals (WPI).
Shareholders of Andrx, based in Fort Lauderdale, Fla., voted Wednesday on a deal that should be completed in the third quarter, the companies said. Watson is based in Corona, Calif.
The $1.9 billion cash transaction must be approved by the Federal Trade Commission, which has twice asked the companies for more information, most recently in early May. For the deal to close, "other various conditions" must be met. The companies didn't provide details.
Although a special Andrx shareholder meeting was scheduled for 10 a.m. EDT, the companies didn't announce the results until after the markets had closed. In regular trading, Andrx closed at $23.42, up 7 cents. After hours, the stock gained 3 cents. Watson's stock closed at $23.32, up 5 cents.
The Andrx-Watson deal represents another example of generic drug-industry consolidation. On Tuesday, Barr Pharmaceuticals (BRL) signed an agreement to pay $2.2 billion for Pliva, a generic-drug company based in Zagreb, Croatia.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
